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Background: This report describe for the first time a clinical case with a CFTR allelic variant 186-8T/C (c.54-8 T/C) in
intron 1 of CFTR and underline the importance of applying a combination of genetic and functional tests to
establish or exclude a diagnosis of Cystic Fibrosis. In this case the diagnostic algorithm proposed for CF has been
successfully applied at our Center and previous CF diagnosis assigned in a different Center was not confirmed.
Case presentation: A 38 year-old Italian woman had been treated as affected by CF since 2010, following
diagnosis based on sweat tests (reported values of 73 and 57 mEq/L) and a clinical history consistent with CF. No
mutations were identified by first level of genetic analysis. Afterwards the patient referred to our center for
assessing the relevance of these findings. The genetic variant 186-8T/C (c.54-8 T/C) in intron 1 of the CFTR gene was
detected by sequencing. Low-level interstitial-alveolar infiltration was recorded by high-resolution computerized
tomography. Lung function was normal and sputum and Broncho Alveolar Lavage cultures resulted bacteriologically
negative. Sweat chloride levels was re-assessed and resulted with values of 57 and 35 mEq/L, with a borderline range
between 40 and 60 mEq/L. Nasal Potential Difference measurements resulted in three reliable measurements consistent
with a non-CF phenotype. Differential diagnosis with ciliary dyskinesia was excluded, as was exon 2 skipping of CFTR
gene that might have caused a CFTR functional defect. Furthermore, single cell fluorescence analysis in response to
cAMP agonists performed in patient’s monocytes overlapped those obtained in healthy donors.
Conclusion: We concluded that this patient was not affected by CF. This case highlights the need for referrals to highly
specialized centers and the importance of combined functional and genetic tests in making a correct diagnosis.
Moreover, we confirmed a correlation between NPD tracings and cell depolarization in monocytes providing a
rationale for proposing the use of leukocytes as a potential support for CF diagnosis.
Keywords: Cystic Fibrosis, Cystic Fibrosis Conductance Transmembrane Regulator, Mutation analysis, Nasal potential
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Cystic Fibrosis (CF) is the most commonly occurring
severe disease with autosomal recessive inheritance in
Caucasians, with an incidence of approximately 1 in 3000,
and among sufferers clinical manifestations vary consider-
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unless otherwise stated.Regulator (CFTR) gene bring about the disease. Up to
now around 1900 mutations in the CFTR gene have been
identified (www.genet.sickkids.on.ca). Most of them are
somewhat rare and this means that genetic test results are
not always sufficient for CF diagnosis [1] and, in addition,
a single genotype may result in different clinical symp-
toms. CF is usually associated with exocrine pancreatic in-
sufficiency, gradual loss of pulmonary function and lung
tissue destruction, but it can also be associated with suffi-
cient residual pancreatic function and a much milder clin-
ical picture [2]. CFTR related disorders [3] include a rangeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Diagnostic algorithm: diagram describing the
diagnostic algorithm utilized for the case described and based
on the proposals from De Boeck et al. [4].
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ated with limited deterioration over time and clinical man-
ifestations in at least one organ in the presence of normal
or borderline sweat chloride values. The borderline range
is between 60 and 40 or 30 mmol/L depending on age and
international guidelines [4,5] with the lowest threshold for
normal values only during the first year of age [4,5] or
always according to De Boeck et al. [4,5]. Sometimes CF
diagnosis is challenging and requires, in addition to
sweat test and genetic analysis, the use of sophisticated
diagnostic tools [6,7]. They aim at testing CFTR func-
tion as ion channel in vivo or ex vivo as under the infer-
ior turbinate of the nose or in rectal biopsies by Nasal
Potential Difference (NPD) measurements or intestinal
current measurements (ICM), respectively. Both these
tests need standardization and validation, and recently
European Standard Operative Procedures have been de-
veloped by the European Cystic Fibrosis Society Diag-
nostic Network Working Group for use as a diagnostic
aid. Other methods measuring ex vivo the functional
properties of CFTR in patients’ tissues utilizing nasal
epithelium [8], leukocytes [9] or intestinal organoids [10]
have been proposed.
Case presentation
Here we report the clinical case of a 38 year-old Italian
woman who, since 2010, had been treated as affected by
CF in a European CF Center. This had followed diagnosis
based on repeated sweat tests (chloride 60 and 74 mEq/L,
normal values <50 mEq/L) and a clinical history consist-
ent with CF (chronic sinusitis, recurrent bronchitis, gall-
stones). Chronic sinusitis was associated with deviation of
the nasal septum treated surgically. Low-level infiltrative
interstitial lung damage was evident from High Resolution
Computerized Tomography (HRCT), bronchiectasis were
absent. No mutations were identified by genetic analysis
performed where the patient was diagnosed as CF. Subse-
quently the CFTR allelic variant 186-8T/C (c.54-8 T/C) in
intron 1 of CFTR gene was identified by gene sequen-
cing in an Italian CF Center where genetic analysis was
performed by reverse dot blot (INNO-LIPA CFTR19,
CFTR17 + TN Update, CFTR Italian Regional), sequen-
cing and Multiplex ligation-dependent probe amplifica-
tion (MLPA). To our knowledge, this is the first time
this allelic variant has been reported. The patient was
then referred to our center for assessment of the rele-
vance of these findings. We then applied a diagnostic al-
gorithm (Figure 1) based on established guidelines [4],
where it is advised to continue the diagnostic work up if
symptoms in a patient persist, as well as when symptoms
have resolved but are highly suspicious for CF such as
pancreatitis or Pseudomonas aeruginosa-associated lung
disease. Wherever the algorithm ends with “CF unlikely”
it is advised to investigate for alternative diagnoses such as
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Shwachman syndrome. For patients with CFTR dysfunc-
tion, the physician needs to decide the most appropriate
diagnostic label (non-classic CF or other WHO diagnostic
definitions in patients with very limited symptoms). Pa-
tients with a borderline sweat test (30–60 mmol/l), only
one CFTR mutation identified, and an inconclusive nasal
potential difference (PD) cannot at present be classified
correctly. They are at least CF carriers. In the presence of
persistent symptoms they need structured follow up at an
appropriate facility (for some patients this may be the CF
centre) and symptomatic treatment. Genetic counseling is
important in these patients and their families. CFTR DNA
test: screening test to search for the most frequent muta-
tions in the population from which the patient originates.
Mutation scanning of CFTR gene: this test is only neces-
sary in some patients in whom the diagnosis cannot be
supported by other means. The tests in the grey area are
optional because two clearly positive sweat tests are suffi-
cient to support the diagnosis of CF in a compatible clin-
ical setting. However, in most CF centres the CFTR DNA
test will be performed to confirm the diagnosis, to allow
for further cascade screening if necessary, and at times for
research purposes. Consult genetic lab: in patients with an
elevated sweat chloride level it would be unusual but not
impossible not to find any mutation. In case of doubt
about the diagnosis, a mutation scanning of the complete
gene can be done. A falsely positive sweat test and the
possibility of CF heterogeneity also need to be considered.
In the case here presented NPD was measured in ac-
cordance with a standardized protocol [6] and normal trac-
ings were obtained. Three repeated measurements were
consistent with a non-CF phenotype. The Wilschanski
index [7] was calculated and results ranged from 0.06 toFigure 2 NDP measurements. The agents indicated at the bottom were
expressed in mV. The graph on the left was obtained from right nostril me
Baseline NPD value was -21 mV. After the addition of amiloride PD increase
NDP measurements were repeated three times and readings were always c0.24, with non-CF values < 0.82 in our Center (Figure 2).
Two consecutive sweat tests were carried out 3 months
apart (on May and July) in accordance with the Gibson
and Cooke method [11] and chloride values of 35 mEq/L
and 57 mEq/L were obtained respectively. The previously
reported sweat test was performed only in the summer fol-
lowing an unspecified method with a local cut-off for nor-
mal value. These might be reasons for discrepancies with
test results from our Center, along with patient’s diet and
hydration levels. It is known that Normal and borderline
sweat tests were obtained in CF patients in the presence
of specific CFTR genotypes: the most representative in-
cludes mutations 3849 + 10 kb C > T, D1152H and
R117H [12,13]. Lung function was normal (forced vital
capacity and forced expiratory volume in the first sec-
ond were both 103% and forced expiratory flow at 25-
75% was 113% of predicted values) and lung infection
was excluded by several sputum cultures and Broncho
Alveolar Lavage (BAL). We have no data available about
eventual differential cell count in BALFs. However nor-
mal pulmonary function tests and negative sputum/BAL
cultures are reported in some CF patients.
We then considered primary ciliary dyskinesia as a
possible, alternative diagnosis. However televideo micro-
scopic technique carried out in a specialized center dis-
played normal ciliary beat and the saccharin test showed
normal ciliary mucus transport, allowing the exclusion
of this disease.
We decided to investigate CFTR-channel function using
NPD analysis and additional ex-vivo and molecular assays,
aimed at supporting the previous findings, were carried
out in parallel. Ferec et al. previously reported a possible
exon 2 splicing in the genetic 186-13C >G variant de-
tected in-trans with F508del in a 13 year old child withadded at the times (minutes) shown on the x-axis. On the y-axis, PD is
asurements; the right one was obtained from left nostril measurements.
d to 13 mV, falling to 2.8 mV after exposure to 0 Cl- and isoproterenol.
onsistent with a non-CF phenotype.
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symptom [14]. Although the T to C substitution is conser-
vative, in this case we aimed to exclude the possibility that
the genetic variant 186-8T/C could affect the splicing.
For this reason, CFTR mRNA from blood cells was ana-
lyzed by RT-PCR, using exon 2 spanning primers or
with primers designed to amplify fragments of different
lengths depending on the presence or absence of exon 2
(Figure 3A). In all cases patient mRNA amplification
products were identified as being the same as in a healthy
donor (Figure 3B). Therefore we concluded that 186-8T/C
mutation does not cause changes in the CFTR cDNA se-
quence despite its localization in intron 1 at position −8.
However, the substitution of T with C is unlikely to be
able to affect splicing since it is conservative in this
polypyrimidine-rich, intronic region.
Further CFTR protein function testing was carried
out using single cell fluorescence analysis in monocytes.
To summarize: the potential-sensitive probe bis-(1,3-
diethylthiobarbituric acid) trimethine oxonol (DiSBAC2
(3) Invitrogen, USA) was used to monitor CFTR-
dependent membrane-potential (Vm) changes. We pre-
viously defined the CF index as an outcome of this assay
and it was shown to be positive in healthy subjects and
negative in CF patients [9]. In the genetic variant 186-
8T/C the CF index was positive (mean: +43 ± 12; n = 2),MK  
100 bp 
HTZ 
186-8T/C
HTZ 
F508del
EXON 1-4 339 bp EXON 2 skipping 207
WT/ 
WT
HTZ 
186-8T/C
HTZ 
F508del
WT/ 
WT
400 bp 
200 bp 
300 bp 
A 
B
Figure 3 Search for CFTR exon 2 skipping by reverse-transcriptase PC
from monocytes was analyzed by RT-PCR using primers designed to ampli
absence of exon 2, to better define if the genetic variant 186-8T/C had cau
reverse-transcribed with random primers. PCR was then carried out for 35 c
Ex 1–4 Forward 5’-AAAGGCCAGCGTTGTCT-3’ (black arrow) or W/O exon 2 F
and the reverse primer, Exon 1–4 5’-GCGATAGAGCGTTCCTC-3’ (black arrow
between the exons 1 and 3 coding sequence, and thus works properly onl
Forward and Reverse primers (black arrows) were expected to be 339 bp. T
PCR-product (228 bp). With the exon-spanning Forward primer (W/O Exon
207 bp. (B) PCR-amplification products: We compared the PCR-amplified pro
heterozygous for the common F508del mutation, and with a healthy subje
obtained from the subject carrying the 186-8T/C variant, using Exon 1–4 Fo
the exon2-spanning primer no amplification products were observed in th
we amplified a portion (290 bp) of the housekeeping gene actin; this PCRa result that overlaps those obtained in monocytes/leu-
kocytes from healthy donors (Figures 4A and 3B).
Doubts about the original CF diagnosis might also
arise from the presence of interstitial infiltration in the
lung in the absence of bronchiectasis and of CFTR
dysfunction-causing mutations in this patient. Since at
our center the patient had normal/ borderline sweat test
values we did not investigate for eventual differential
diagnosis with diseases associated with a raise in elec-
trolyte levels [15].
In the case reported, the application at our Center of
the CF diagnostic algorithm [4] was successful and the
previous CF-diagnosis was not confirmed (Figure 1). Our
interpretation of NPD data seems in agreement with the
recommendation provided by Boucher [16] who under-
lined the importance to correctly evaluate sodium trans-
port to establish a correct diagnosis when NPD are
required. Based on a French study he proposed bronchiec-
tasis to be a multiple hits process or a continuum of ion
transport dysfunction measured by NPD according to
presence of zero, one or two mutations or genetic vari-
ants. Diffuse bronchiectasis are a possible phenotype of
CFTR related disorders. In this patients no bronchiectasis
were evident by HRCT and low-level infiltrative interstitial
lung damage in conjunction with recurrent bronchitis are
still of unknown origin. bp ACTIN 290 bp
MK  
100 bp 
HTZ 
186-8T/C
HTZ 
F508del
WT/ 
WT
NC 
EX1-4
NC 
W/o EX2 
NC 
actin
R amplification of mRNA from monocytes. (A) RT-PCR design: mRNA
fy fragments of different length, depending on the presence or
sed alternative splicing in this subject. Total RNA was purified and
ycles (30” at 94°C, 30” at 60°C, 30” at 72°C) using the forward primer,
orward primer 5’-ACTTTTTTTCAGAGAATGGGATAGAG-3’ (gray arrow),
). The exon-spanning primer “W/O exon 2 Forward primer” is localized
y in the absence of exon 2. Amplified fragment lengths using Exon1-4
herefore, in the case of exon 2 skipping, we would expect a shorter
2; grey arrow) we expected an amplified product of a length of
ducts obtained from the patient (186–8 T/C), with a healthy subject
ct (no mutations) as internal control. The amplification product
rw/Rev primers, was undistinguishable from controls, moreover, using
e samples from any of the subjects (Negative Controls-NC). As control
was then carried out for 25 cycle.
CF HTZ NOT CF 186-8 T/C 
CF
 IN
D
EX
 
A 
B
not-CF 
CF  stop/stop 
CF  
index 
HTZ F508del 
HTZ 186-8 T/C 
Figure 4 Diagnostic algorithm. (A) Monocyte cell membrane depolarization assay. Single cell fluorescence assay was performed as described10.
Measurements of the cell membrane depolarization were obtained in a extracellular environment lacking chloride-ion and were measured at two
different conditions: under basal conditions (empty boxes), or with a stimulus-cocktail consisting of 8-Br-cAMP, Forkolin and IBMX (filled boxes)
added at the 5th minute. Percentage of DiSBAC2(3) fluorescence variation (ΔF) is shown over time according to the equation: ΔFt = [(Ft-F0)/F0]
*100, where Ft and F0 are the fluorescence values at time t and at the time t0 (5th minute). The difference between the maximum fluorescence
values obtained on stimulation (filled boxes) and the matching fluorescence under basal conditions (empty boxes) represents the CF index. We
defined the CF index outcome for this assay being a positive value in healthy subjects and a negative value in CF patients. A typical non-CF
pattern, where a higher signal can be observed after stimulation, is represented at the top-left panel, with a CF index of +116. On the other hand,
when monocytes from a subject carrying a non-sense mutation on both alleles were used, the opposite trend was observed (bottom-left panel),
with a negative CF index of −25,2. With the monocytes from the patient (186-8T/C) a positive CF index was obtained (43 ± 12; n = 2; right-bottom
panel), with a response to the cAMP-analogue similar to those obtained from the other HTZ subject (CF = +22; right-up panel). (B) CF index. Plotting of
the CF index values obtained from the subject in comparison with recording from patients and controls performed in our laboratory using the same
experimental setting. Number of Samples: CF subjects n = 40, HTZ subjects n = 28 and non CF subjects n = 31. Analysis of the 186–8 T/C subject was
repeated twice (technical duplicate).
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wrong diagnosis of CF for a patient and relatives in
terms of medical, psychological, social and insurance
implications. It is indeed a chronic progressive disease
compromising quality and expectancy of life. Consider-
ing its autosomal recessive inheritance also for genetic
counselling it is very relevant to avoid wrong diagnosis,
in particular in this case having no disease causing mu-
tations identified.This outlines how important is for the CF community to
have access to clinical and electrophysiological informa-
tion on rare mutations; it can lead to further improve-
ments in diagnostic procedure and genetic counseling. A
large number of genetic variants of uncertain functional
significance have been identified due to the extensive se-
quencing being carried out, diluting the practical applica-
tion of this valuable information [17,18]. Besides CFTR,
several modifier genes have also been described as being
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tests are under development [20] but need to be vali-
dated and standardized assays are available only for
NPD and intestinal current measurements [21]. Both
these measurements are minimally invasive and can be
used in selected cases.
Conclusion
In the clinical case reported here, sweat tests and genetic
analysis were inconclusive and CFTR functional testing,
in accordance with a standard method (NPD), was car-
ried out. In addition, we evaluated a possible exon skip-
ping and CFTR function in leukocytes. None of the
results obtained at our Center were consistent with CF
diagnosis. An innovative approach using leukocytes was
also applied, being potentially more convenient than
currently available and standardized approaches. Valid-
ation with a large group of subjects is in progress and
research to develop simpler, more feasible functional as-
says in leukocytes and epithelial cells are underway in
our and in other Centres, with the aim of providing add-
itional tools for testing genetic variants of uncertain clin-
ical relevance as well as the effects of drugs targeting the
basic CF defect.
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